Left ventricular structure and geometry, peripheral artery endotheliumdependent vasodilatation, antihypertensive effect of ACE inhibitors, and hormone replacement therapy in premenopausal women with arterial hypertension

Aim.To summarize the data on the 7-month treatment with ACE inhibitors (lisinopril) and hormone replacement therapy, HRT (femoston) – in particular, the effects on left ventricular (LV) structure and geometry, peripheral artery endothelium-dependent vasodilatation (EDVD), blood pressure (BP), and clinical perimenopausal symptoms – in premenopausal women with arterial hypertension (AH).Material and methods.The study included 84 premenopausal women with Stage II AH and LV myocardial hypertrophy (LVH). Group I (47 women; mean age 48,6 years). The clinical symptoms included nighttime hyperhidrosis and hot flashes. In Group II (37 women, mean age 53,2 years). The clinical symptoms in Group II participants included hyperhidrosis, hot flashes, malaise, and dysphoria. Group II received lisinopril (1– mg/day) and femoston (2/10/2 mg); Group I was administered lisinopril in the same dose and placebo. Clinical examination, the measurement of BP and heart rate (HR), ECG, EDVD assessment, and echocardiography (EchoCG) were performed at baseline, during the treatment, and 7 months after the end of the treatment.Results.Lisinopril therapy demonstrated a good antihypertensive effect in premenopausal women with AH, while also preventing the progression of LVH and dilatation of left heart chambers.Conclusion.The studied medications improved peripheral artery endothelial function and were well tolerated. Femoston was highly compatible with cardiac therapy and effectively reduced clinical symptoms in premenopausal women with AH.